All In Biotech

Drug Trial Radar · NCT00002651

SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer

Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III

Last checked: Nov 19, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,040 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,040

Actual

Start

May 1995

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; European Organisation for Research and Treatment of Cancer - EORTC
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer. It is not yet known which regimen of hormone therapy is most effective for stage IV prostate cancer. PURPOSE: This randomized phase III trial is studying two different regimens of hormone therapy and comparing how well they work in treating men with stage IV prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • bicalutamideDrug

    Given orally

  • goserelin acetateDrug

    Given subcutaneously

  • clinical observationOther

    Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Up to 15 years
  2. Physical Functioning as Measured by the SF-36Time frame: 3 months
  3. Emotional Functioning as Measured by the SF-36 Mental Health InventoryTime frame: 3 months
  4. Erectile DysfunctionTime frame: 3 months
  5. High LibidoTime frame: 3 months
  6. VitalityTime frame: 3 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Tom Baker Cancer Centre - Calgary

    Calgary, Alberta, Canada

  • Cross Cancer Institute at University of Alberta

    Edmonton, Alberta, Canada

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • Nova Scotia Cancer Centre

    Halifax, Nova Scotia, Canada

  • Cancer Centre of Southeastern Ontario at Kingston General Hospital

    Kingston, Ontario, Canada

  • London Regional Cancer Program at London Health Sciences Centre

    London, Ontario, Canada

  • Ottawa Hospital Regional Cancer Centre - General Campus

    Ottawa, Ontario, Canada

  • Odette Cancer Centre at Sunnybrook

    Toronto, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Hopital Notre-Dame du CHUM

    Montreal, Quebec, Canada

  • McGill Cancer Centre at McGill University

    Montreal, Quebec, Canada

  • Centre Hospitalier Universitaire de Quebec

    Québec, Quebec, Canada

  • CHUS-Hopital Fleurimont

    Sherbrooke, Quebec, Canada

  • Saskatoon Cancer Centre at the University of Saskatchewan

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.